Index of /wp-content/uploads/2025/02

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[IMG]medeye-merki-2017-1.jpg2025-02-21 15:39 224K 
[IMG]medeye-merki-2017-1-768x768.jpg2025-02-21 15:39 80K 
[IMG]medeye-merki-2017-1-500x500.jpg2025-02-21 15:39 55K 
[IMG]medeye-merki-2017-1-300x300.jpg2025-02-21 15:39 39K 
[IMG]medeye-merki-2017-1-150x150.jpg2025-02-21 15:39 29K 
[IMG]journal-mars-2025.png2025-02-28 13:31 479K 
[IMG]journal-mars-2025-500x500.png2025-02-28 13:31 258K 
[IMG]journal-mars-2025-225x300.png2025-02-28 13:31 88K 
[IMG]journal-mars-2025-150x150.png2025-02-28 13:31 37K 
[IMG]csl-vifor.svg2025-02-28 13:54 1.6K 
[IMG]csl-vifor-1.svg2025-02-28 13:58 1.6K 
[IMG]biocon-logo.png2025-02-28 13:18 84K 
[IMG]biocon-logo-1536x343.png2025-02-28 13:18 66K 
[IMG]biocon-logo-1024x229.png2025-02-28 13:18 41K 
[IMG]biocon-logo-768x172.png2025-02-28 13:18 30K 
[IMG]biocon-logo-500x430.png2025-02-28 13:18 13K 
[IMG]biocon-logo-300x67.png2025-02-28 13:18 11K 
[IMG]biocon-logo-150x150.png2025-02-28 13:18 5.1K 
[IMG]baxter-blu-copy.jpg2025-02-26 09:01 82K 
[IMG]baxter-blu-copy-768x768.jpg2025-02-26 09:01 29K 
[IMG]baxter-blu-copy-500x500.jpg2025-02-26 09:01 20K 
[IMG]baxter-blu-copy-300x300.jpg2025-02-26 09:01 14K 
[IMG]baxter-blu-copy-150x150.jpg2025-02-26 09:01 10K 
[IMG]add-journal.jpg2025-02-28 10:50 337K 
[IMG]add-journal-1151x1536.jpg2025-02-28 10:50 153K 
[IMG]add-journal-768x1025.jpg2025-02-28 10:50 91K 
[IMG]add-journal-767x1024.jpg2025-02-28 10:50 90K 
[IMG]add-journal-500x500.jpg2025-02-28 10:50 43K 
[IMG]add-journal-225x300.jpg2025-02-28 10:50 19K 
[IMG]add-journal-150x150.jpg2025-02-28 10:50 11K 
[IMG]V4_CSLVifor_Logo_rgb.jpg2025-02-28 13:03 144K 
[IMG]V4_CSLVifor_Logo_rgb-1536x341.jpg2025-02-28 13:03 64K 
[IMG]V4_CSLVifor_Logo_rgb-1024x228.jpg2025-02-28 13:03 48K 
[IMG]V4_CSLVifor_Logo_rgb-768x171.jpg2025-02-28 13:03 39K 
[IMG]V4_CSLVifor_Logo_rgb-500x375.jpg2025-02-28 13:03 31K 
[IMG]V4_CSLVifor_Logo_rgb-300x67.jpg2025-02-28 13:03 26K 
[IMG]V4_CSLVifor_Logo_rgb-150x150.jpg2025-02-28 13:03 21K 
[IMG]Sotiris_Tsiafos_Tsiaras.jpg2025-02-07 17:31 2.0M 
[IMG]Sotiris_Tsiafos_Tsiaras-1366x2048.jpg2025-02-07 17:31 399K 
[IMG]Sotiris_Tsiafos_Tsiaras-1024x1536.jpg2025-02-07 17:31 240K 
[IMG]Sotiris_Tsiafos_Tsiaras-768x1151.jpg2025-02-07 17:31 140K 
[IMG]Sotiris_Tsiafos_Tsiaras-683x1024.jpg2025-02-07 17:31 111K 
[IMG]Sotiris_Tsiafos_Tsiaras-500x500.jpg2025-02-07 17:31 42K 
[IMG]Sotiris_Tsiafos_Tsiaras-200x300.jpg2025-02-07 17:31 10K 
[IMG]Sotiris_Tsiafos_Tsiaras-150x150.jpg2025-02-07 17:31 5.2K 
[ ]SOP_External-Relations_v0.2-Feb2025-Copy.docx2025-02-17 10:18 364K 
[ ]SOP_External-Attendance_v0.2-Feb2025-Copy.docx2025-02-17 10:16 367K 
[ ]SOP-congress-opening-and-closing-Feb25-v4.docx2025-02-17 10:14 72K 
[ ]SOP-collecting-membership-dues-Feb2025-v3.doc2025-02-17 10:11 405K 
[ ]SOP-collecting-membership-dues-Feb2025-v3-3.doc2025-02-17 10:12 405K 
[ ]SOP-collecting-membership-dues-Feb2025-v3-2.doc2025-02-17 10:11 405K 
[ ]SOP-collecting-membership-dues-Feb2025-v3-1.doc2025-02-17 10:11 405K 
[ ]SOP-Special-Interest-Groups-6Sep2022.docx2025-02-17 10:41 740K 
[ ]SOP-Special-Interest-Groups-6Sep2022-1.docx2025-02-17 10:41 740K 
[ ]SOP-Scientific-Committee-vMay2024.doc2025-02-17 10:27 768K 
[ ]SOP-Responding-to-consultations-v0.1Jan-21.docx2025-02-17 10:14 364K 
[ ]SOP-Organising-Congress-March2024-V1.docx2025-02-17 10:25 2.0M 
[ ]SOP-New-Members-25Jan14v.02.docx2025-02-17 10:22 742K 
[ ]SOP-Member-projects-16Jan23-v2.docx2025-02-17 10:21 369K 
[IMG]SIDAM_Logo_cmyk.jpg2025-02-04 12:59 702K 
[IMG]SIDAM_Logo_cmyk-768x768.jpg2025-02-04 12:59 604K 
[IMG]SIDAM_Logo_cmyk-500x500.jpg2025-02-04 12:59 585K 
[IMG]SIDAM_Logo_cmyk-300x300.jpg2025-02-04 12:59 572K 
[IMG]SIDAM_Logo_cmyk-150x150.jpg2025-02-04 12:59 563K 
[VID]Pharma-Search-Demonst.-Video.mp42025-03-25 14:03 49M 
[IMG]Pentapack-logo-copy.jpg2025-02-03 16:40 125K 
[IMG]Pentapack-logo-copy-768x768.jpg2025-02-03 16:40 45K 
[IMG]Pentapack-logo-copy-500x500.jpg2025-02-03 16:40 29K 
[IMG]Pentapack-logo-copy-300x300.jpg2025-02-03 16:40 19K 
[IMG]Pentapack-logo-copy-150x150.jpg2025-02-03 16:40 13K 
[IMG]Patrick-Koch.jpg2025-02-14 17:42 6.6K 
[IMG]Patrick-Koch-150x150.jpg2025-02-14 17:42 5.0K 
[ ]NP_007.pdf2025-02-27 17:28 963K 
[ ]NP-008.pdf2025-02-27 17:28 503K 
[ ]NP-006.pdf2025-02-19 13:05 1.2M 
[ ]NP-005.pdf2025-02-19 13:05 643K 
[ ]NP-003.pdf2025-02-19 13:05 500K 
[ ]NP-001.pdf2025-02-28 16:50 291K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25.jpg2025-02-28 13:03 67K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25-1024x163.jpg2025-02-28 13:03 21K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25-768x122.jpg2025-02-28 13:03 15K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25-500x200.jpg2025-02-28 13:03 11K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25-300x48.jpg2025-02-28 13:03 4.2K 
[IMG]NON-2025-00017-GL-EAHP-Website-Banner-Booth-24-02-25-150x150.jpg2025-02-28 13:03 3.1K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25.jpg2025-02-28 13:03 68K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25-1024x163.jpg2025-02-28 13:03 21K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25-768x122.jpg2025-02-28 13:03 15K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25-500x200.jpg2025-02-28 13:03 12K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25-300x48.jpg2025-02-28 13:03 4.3K 
[IMG]NON-2025-00016-GL-EAHP-Website-Banner-Satellite-Symposium-24-02-25-150x150.jpg2025-02-28 13:03 2.8K 
[IMG]Molnlycke.jpg2025-02-05 15:32 640K 
[IMG]Molnlycke-768x768.jpg2025-02-05 15:32 579K 
[IMG]Molnlycke-500x500.jpg2025-02-05 15:32 566K 
[IMG]Molnlycke-300x300.jpg2025-02-05 15:32 559K 
[IMG]Molnlycke-150x150.jpg2025-02-05 15:32 554K 
[ ]MRVZ-BBOM.pdf2025-02-28 13:03 1.2M 
[IMG]JVM_logo_CMYK-copy.jpg2025-02-17 15:24 143K 
[IMG]JVM_logo_CMYK-copy-768x768.jpg2025-02-17 15:24 51K 
[IMG]JVM_logo_CMYK-copy-500x500.jpg2025-02-17 15:24 35K 
[IMG]JVM_logo_CMYK-copy-300x300.jpg2025-02-17 15:24 24K 
[IMG]JVM_logo_CMYK-copy-150x150.jpg2025-02-17 15:24 17K 
[IMG]Image-FS.jpg2025-02-05 10:14 14K 
[IMG]Image-FS-2048x2048.jpg2025-02-05 10:14 215K 
[IMG]Image-FS-1536x1536.jpg2025-02-05 10:14 136K 
[IMG]Image-FS-1024x1024.jpg2025-02-05 10:14 71K 
[IMG]Image-FS-768x768.jpg2025-02-05 10:14 44K 
[IMG]Image-FS-500x500.jpg2025-02-05 10:14 23K 
[IMG]Image-FS-300x300.jpg2025-02-05 10:14 11K 
[IMG]Image-FS-150x150.jpg2025-02-05 10:14 4.2K 
[IMG]IMG_20250204_145157.jpg2025-02-04 14:52 342K 
[IMG]IMG_20250204_145157-2048x2048.jpg2025-02-04 14:52 241K 
[IMG]IMG_20250204_145157-1536x1536.jpg2025-02-04 14:52 148K 
[IMG]IMG_20250204_145157-1024x1024.jpg2025-02-04 14:52 75K 
[IMG]IMG_20250204_145157-768x781.jpg2025-02-04 14:52 48K 
[IMG]IMG_20250204_145157-500x500.jpg2025-02-04 14:52 25K 
[IMG]IMG_20250204_145157-300x300.jpg2025-02-04 14:52 12K 
[IMG]IMG_20250204_145157-150x150.jpg2025-02-04 14:52 4.9K 
[IMG]IMG_7507.jpeg2025-02-10 10:51 725K 
[IMG]IMG_7507-2048x2048.jpeg2025-02-10 10:51 180K 
[IMG]IMG_7507-1536x1536.jpeg2025-02-10 10:51 115K 
[IMG]IMG_7507-1024x1024.jpeg2025-02-10 10:51 63K 
[IMG]IMG_7507-768x1020.jpeg2025-02-10 10:51 56K 
[IMG]IMG_7507-500x500.jpeg2025-02-10 10:51 23K 
[IMG]IMG_7507-300x300.jpeg2025-02-10 10:51 11K 
[IMG]IMG_7507-150x150.jpeg2025-02-10 10:51 4.4K 
[IMG]Harrath-Rabeh-EAHP.jpg2025-02-04 14:51 682K 
[IMG]Harrath-Rabeh-EAHP-2048x2048.jpg2025-02-04 14:51 231K 
[IMG]Harrath-Rabeh-EAHP-1536x1536.jpg2025-02-04 14:51 141K 
[IMG]Harrath-Rabeh-EAHP-1024x1024.jpg2025-02-04 14:51 72K 
[IMG]Harrath-Rabeh-EAHP-768x1142.jpg2025-02-04 14:51 61K 
[IMG]Harrath-Rabeh-EAHP-500x500.jpg2025-02-04 14:51 24K 
[IMG]Harrath-Rabeh-EAHP-300x300.jpg2025-02-04 14:51 12K 
[IMG]Harrath-Rabeh-EAHP-150x150.jpg2025-02-04 14:51 4.9K 
[IMG]HPD202551-1.png2025-02-17 10:12 193K 
[IMG]HPD202551-1-1536x1536.png2025-02-17 10:12 196K 
[IMG]HPD202551-1-1024x1024.png2025-02-17 10:12 108K 
[IMG]HPD202551-1-768x768.png2025-02-17 10:12 73K 
[IMG]HPD202551-1-500x500.png2025-02-17 10:12 43K 
[IMG]HPD202551-1-300x300.png2025-02-17 10:12 24K 
[IMG]HPD202551-1-150x150.png2025-02-17 10:12 10K 
[IMG]Esra-Furuncu.jpg2025-02-14 17:26 1.4M 
[IMG]Esra-Furuncu-1479x2048.jpg2025-02-14 17:26 271K 
[IMG]Esra-Furuncu-1109x1536.jpg2025-02-14 17:26 166K 
[IMG]Esra-Furuncu-768x1064.jpg2025-02-14 17:26 92K 
[IMG]Esra-Furuncu-739x1024.jpg2025-02-14 17:26 86K 
[IMG]Esra-Furuncu-500x500.jpg2025-02-14 17:26 43K 
[IMG]Esra-Furuncu-217x300.jpg2025-02-14 17:26 23K 
[IMG]Esra-Furuncu-150x150.jpg2025-02-14 17:26 18K 
[IMG]Eleni-S.-Evangelatou.jpg2025-02-07 16:39 117K 
[IMG]Eleni-S.-Evangelatou-500x500.jpg2025-02-07 16:39 58K 
[IMG]Eleni-S.-Evangelatou-300x287.jpg2025-02-07 16:39 34K 
[IMG]Eleni-S.-Evangelatou-150x150.jpg2025-02-07 16:39 21K 
[IMG]Ecolab_LS_Blue_RGB-copy.jpg2025-02-10 17:09 105K 
[IMG]Ecolab_LS_Blue_RGB-copy-768x768.jpg2025-02-10 17:09 40K 
[IMG]Ecolab_LS_Blue_RGB-copy-500x500.jpg2025-02-10 17:09 27K 
[IMG]Ecolab_LS_Blue_RGB-copy-300x300.jpg2025-02-10 17:09 18K 
[IMG]Ecolab_LS_Blue_RGB-copy-150x150.jpg2025-02-10 17:09 12K 
[IMG]Chiara-Lamesta.jpg2025-02-03 18:34 440K 
[IMG]Chiara-Lamesta-813x1024.jpg2025-02-03 18:34 121K 
[IMG]Chiara-Lamesta-768x967.jpg2025-02-03 18:34 109K 
[IMG]Chiara-Lamesta-500x500.jpg2025-02-03 18:34 44K 
[IMG]Chiara-Lamesta-238x300.jpg2025-02-03 18:34 15K 
[IMG]Chiara-Lamesta-150x150.jpg2025-02-03 18:34 5.8K 
[IMG]Capture-decran-2025-02-28-a-13.49.01.png2025-02-28 13:49 150K 
[IMG]Capture-decran-2025-02-28-a-13.49.01-1024x232.png2025-02-28 13:49 97K 
[IMG]Capture-decran-2025-02-28-a-13.49.01-768x174.png2025-02-28 13:49 62K 
[IMG]Capture-decran-2025-02-28-a-13.49.01-500x256.png2025-02-28 13:49 41K 
[IMG]Capture-decran-2025-02-28-a-13.49.01-300x68.png2025-02-28 13:49 15K 
[IMG]Capture-decran-2025-02-28-a-13.49.01-150x150.png2025-02-28 13:49 9.6K 
[IMG]Capture-decran-2025-02-28-a-13.48.49.png2025-02-28 13:49 21K 
[IMG]Capture-decran-2025-02-28-a-13.48.49-201x300.png2025-02-28 13:49 15K 
[IMG]Capture-decran-2025-02-28-a-13.48.49-150x150.png2025-02-28 13:49 9.2K 
[IMG]CSL-Vifor.webp2025-02-28 15:06 11K 
[IMG]CSL-Vifor-500x430.webp2025-02-28 15:06 8.2K 
[IMG]CSL-Vifor-300x168.webp2025-02-28 15:06 5.6K 
[IMG]CSL-Vifor-150x150.webp2025-02-28 15:06 2.7K 
[IMG]CSL-Vifor-2.png2025-02-28 13:16 120K 
[IMG]CSL-Vifor-2-1024x161.png2025-02-28 13:16 90K 
[IMG]CSL-Vifor-2-768x121.png2025-02-28 13:16 59K 
[IMG]CSL-Vifor-2-500x198.png2025-02-28 13:16 33K 
[IMG]CSL-Vifor-2-300x47.png2025-02-28 13:16 15K 
[IMG]CSL-Vifor-2-150x150.png2025-02-28 13:16 13K 
[IMG]CSL-Vifor-1.png2025-02-28 13:16 117K 
[IMG]CSL-Vifor-1-1024x161.png2025-02-28 13:16 88K 
[IMG]CSL-Vifor-1-768x121.png2025-02-28 13:16 58K 
[IMG]CSL-Vifor-1-500x198.png2025-02-28 13:16 32K 
[IMG]CSL-Vifor-1-300x47.png2025-02-28 13:16 15K 
[IMG]CSL-Vifor-1-150x150.png2025-02-28 13:16 14K 
[ ]CPH-Travel-Pass_EAHP-Congress2025.pdf2025-02-14 14:41 129K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E.jpeg2025-02-05 10:33 359K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-2048x2048.jpeg2025-02-05 10:33 483K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-1536x1536.jpeg2025-02-05 10:33 303K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-1024x1024.jpeg2025-02-05 10:33 154K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-768x642.jpeg2025-02-05 10:33 83K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-500x500.jpeg2025-02-05 10:33 46K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-300x300.jpeg2025-02-05 10:33 19K 
[IMG]C7D6FF66-C2B5-4FDD-8E8F-9EE539DFD42E-150x150.jpeg2025-02-05 10:33 6.3K 
[IMG]Biovalley-Investments-Parter-SpA-ChemoMaker.jpg2025-02-06 16:34 776K 
[IMG]Biovalley-Investments-Parter-SpA-ChemoMaker-768x768.jpg2025-02-06 16:34 627K 
[IMG]Biovalley-Investments-Parter-SpA-ChemoMaker-500x500.jpg2025-02-06 16:34 600K 
[IMG]Biovalley-Investments-Parter-SpA-ChemoMaker-300x300.jpg2025-02-06 16:34 582K 
[IMG]Biovalley-Investments-Parter-SpA-ChemoMaker-150x150.jpg2025-02-06 16:34 571K 
[IMG]Biocon-Logo.jpg2025-02-07 14:39 660K 
[IMG]Biocon-Logo-768x768.jpg2025-02-07 14:39 588K 
[IMG]Biocon-Logo-500x500.jpg2025-02-07 14:39 574K 
[IMG]Biocon-Logo-300x300.jpg2025-02-07 14:39 563K 
[IMG]Biocon-Logo-150x150.jpg2025-02-07 14:39 557K 
[IMG]Baxter-Synergy-3.jpg2025-02-06 08:45 560K 
[ ]BBL.pdf2025-02-28 13:03 887K 
[IMG]Adrin-Dadkhah.jpg2025-02-03 18:15 1.5M 
[IMG]Adrin-Dadkhah-scaled.jpg2025-02-03 18:15 342K 
[IMG]Adrin-Dadkhah-1365x2048.jpg2025-02-03 18:15 228K 
[IMG]Adrin-Dadkhah-1024x1536.jpg2025-02-03 18:15 142K 
[IMG]Adrin-Dadkhah-768x1152.jpg2025-02-03 18:15 96K 
[IMG]Adrin-Dadkhah-683x1024.jpg2025-02-03 18:15 84K 
[IMG]Adrin-Dadkhah-500x500.jpg2025-02-03 18:15 56K 
[IMG]Adrin-Dadkhah-200x300.jpg2025-02-03 18:15 39K 
[IMG]Adrin-Dadkhah-150x150.jpg2025-02-03 18:15 35K 
[ ]Ac29-Exhibitors-Map.pdf2025-02-28 09:11 8.4M 
[ ]AC29-v6-Mini-Programme-Book-A6-Cop-2025-for-PRINT.pdf2025-02-18 16:27 725K 
[ ]AC29-Mini-Programme-Book.pdf2025-02-20 11:56 725K 
[IMG]1000031495.jpg2025-02-04 11:50 1.8M 
[IMG]1000031495-scaled.jpg2025-02-04 11:50 726K 
[IMG]1000031495-2048x2048.jpg2025-02-04 11:50 486K 
[IMG]1000031495-1536x1536.jpg2025-02-04 11:50 281K 
[IMG]1000031495-1024x1024.jpg2025-02-04 11:50 128K 
[IMG]1000031495-768x576.jpg2025-02-04 11:50 57K 
[IMG]1000031495-500x500.jpg2025-02-04 11:50 35K 
[IMG]1000031495-300x300.jpg2025-02-04 11:50 15K 
[IMG]1000031495-150x150.jpg2025-02-04 11:50 5.1K 
[IMG]1000019653.jpg2025-02-25 17:24 5.9M 
[IMG]1000019653-scaled.jpg2025-02-25 17:24 452K 
[IMG]1000019653-2048x2048.jpg2025-02-25 17:24 302K 
[IMG]1000019653-1536x1536.jpg2025-02-25 17:24 180K 
[IMG]1000019653-1024x1024.jpg2025-02-25 17:24 89K 
[IMG]1000019653-768x511.jpg2025-02-25 17:24 32K 
[IMG]1000019653-500x500.jpg2025-02-25 17:24 26K 
[IMG]1000019653-300x300.jpg2025-02-25 17:24 12K 
[IMG]1000019653-150x150.jpg2025-02-25 17:24 4.1K 
[ ]6ER-048.pdf2025-02-27 17:28 3.9M 
[ ]6ER-046.pdf2025-02-17 13:23 525K 
[ ]6ER-045.pdf2025-02-27 17:28 779K 
[ ]6ER-044.pdf2025-02-27 17:28 428K 
[ ]6ER-043.pdf2025-02-27 17:28 592K 
[ ]6ER-042.pdf2025-02-27 17:28 884K 
[ ]6ER-041.pdf2025-02-28 08:38 259K 
[ ]6ER-040.pdf2025-02-27 17:28 503K 
[ ]6ER-039.pdf2025-02-28 16:50 209K 
[ ]6ER-038.pdf2025-02-27 17:28 1.0M 
[ ]6ER-037.pdf2025-02-27 17:28 930K 
[ ]6ER-036.pdf2025-02-27 17:28 906K 
[ ]6ER-035.pdf2025-02-14 16:03 336K 
[ ]6ER-035-1.pdf2025-02-17 13:23 336K 
[ ]6ER-031-.pdf2025-02-28 16:50 103K 
[ ]6ER-030.pdf2025-02-28 16:50 241K 
[ ]6ER-029-.pdf2025-02-28 16:50 495K 
[ ]6ER-028.pdf2025-02-27 17:28 773K 
[ ]6ER-026.pdf2025-02-27 17:28 4.0M 
[ ]6ER-025.pdf2025-02-27 17:28 617K 
[ ]6ER-024.pdf2025-02-19 13:07 874K 
[ ]6ER-023-.pdf2025-02-27 17:28 447K 
[ ]6ER-022.pdf2025-02-17 13:23 163K 
[ ]6ER-021.pdf2025-02-27 17:28 547K 
[ ]6ER-019.pdf2025-02-27 17:28 874K 
[ ]6ER-018.pdf2025-02-17 13:23 1.4M 
[ ]6ER-016.pdf2025-02-27 17:28 903K 
[ ]6ER-015.pdf2025-02-17 13:23 491K 
[ ]6ER-013.pdf2025-02-17 13:23 341K 
[ ]6ER-012.pdf2025-02-17 13:23 583K 
[ ]6ER-011.pdf2025-02-17 13:23 588K 
[ ]6ER-010.pdf2025-02-17 13:23 1.3M 
[ ]6ER-009.pdf2025-02-17 13:23 232K 
[ ]6ER-008.pdf2025-02-27 17:28 833K 
[ ]6ER-007.pdf2025-02-17 13:23 1.0M 
[ ]6ER-006.pdf2025-02-17 13:23 285K 
[ ]6ER-005.pdf2025-02-28 13:58 872K 
[ ]6ER-005-1.pdf2025-02-28 16:43 872K 
[ ]6ER-004.pdf2025-02-17 13:23 401K 
[ ]6ER-003.pdf2025-02-17 13:23 128K 
[ ]5psq-042.pdf2025-02-27 17:56 4.3M 
[ ]5PSQ-155.pdf2025-02-27 17:41 780K 
[ ]5PSQ-154-Dr-Rinaudo.pdf2025-02-27 17:41 395K 
[ ]5PSQ-153.pdf2025-02-27 17:41 271K 
[ ]5PSQ-152.pdf2025-02-28 13:58 473K 
[ ]5PSQ-152-1.pdf2025-02-28 16:43 473K 
[ ]5PSQ-151-INCIDENCE-OF-NEPHROTOXICITY-IN-CISPLATIN-ADMINISTRATION-ASSOCIATED-WITH-A-HYDRATION-PROTOCOL.pdf2025-02-27 17:41 180K 
[ ]5PSQ-150.pdf2025-02-28 08:38 1.0M 
[ ]5PSQ-147.pdf2025-02-17 13:36 668K 
[ ]5PSQ-147-1.pdf2025-02-27 17:41 663K 
[ ]5PSQ-146.pdf2025-02-17 13:36 403K 
[ ]5PSQ-144.pdf2025-02-27 17:41 1.2M 
[ ]5PSQ-143.pdf2025-02-28 08:38 1.1M 
[ ]5PSQ-141.pdf2025-02-27 17:41 245K 
[ ]5PSQ-140.pdf2025-02-27 17:41 94K 
[ ]5PSQ-139.pdf2025-02-27 17:41 257K 
[ ]5PSQ-138.pdf2025-02-17 13:36 656K 
[ ]5PSQ-137.pdf2025-02-17 13:36 208K 
[ ]5PSQ-137-PROGNOSTIC-ROLE-OF-HAEMATOLOGICAL-PARAMETERS-IN-EXTENDED-STAGE-SMALL-CELL-LUNG-CANCER-PATIENTS-TREATED-WITH-ATEZOLIZUMAB-IN-COMBINATION-WITH-CHEMOTHERAPY-.pdf2025-02-19 13:07 679K 
[ ]5PSQ-136.pdf2025-02-27 17:41 103K 
[ ]5PSQ-133.pdf2025-02-27 17:41 337K 
[ ]5PSQ-132.pdf2025-02-19 13:07 287K 
[ ]5PSQ-130.pdf2025-02-17 13:36 506K 
[ ]5PSQ-129.pdf2025-02-27 17:41 795K 
[ ]5PSQ-126.pdf2025-02-17 13:36 529K 
[ ]5PSQ-125.pdf2025-02-27 17:41 1.1M 
[ ]5PSQ-124.pdf2025-02-19 13:07 771K 
[ ]5PSQ-122.pdf2025-02-17 13:36 248K 
[ ]5PSQ-120.pdf2025-02-27 17:41 621K 
[ ]5PSQ-119.pdf2025-02-27 17:41 384K 
[ ]5PSQ-118.pdf2025-02-28 13:58 917K 
[ ]5PSQ-118-1.pdf2025-02-28 16:43 917K 
[ ]5PSQ-117.pdf2025-02-17 13:36 238K 
[ ]5PSQ-116.pdf2025-02-17 13:36 386K 
[ ]5PSQ-115.pdf2025-02-28 16:50 536K 
[ ]5PSQ-114.pdf2025-02-27 17:41 160K 
[ ]5PSQ-113.pdf2025-02-27 17:48 269K 
[ ]5PSQ-112.pdf2025-02-17 13:36 892K 
[ ]5PSQ-109.pdf2025-02-17 13:36 219K 
[ ]5PSQ-108.pdf2025-02-28 08:38 629K 
[ ]5PSQ-107.pdf2025-02-27 17:48 369K 
[ ]5PSQ-106.pdf2025-02-27 17:48 761K 
[ ]5PSQ-105.pdf2025-02-27 17:48 325K 
[ ]5PSQ-104.pdf2025-02-17 13:36 265K 
[ ]5PSQ-103.pdf2025-02-17 13:36 2.6M 
[ ]5PSQ-102.pdf2025-02-17 14:01 885K 
[ ]5PSQ-101.-Fosaprepitant.pdf2025-02-27 17:48 88K 
[ ]5PSQ-100.pdf2025-02-27 17:48 316K 
[ ]5PSQ-099.pdf2025-02-27 17:47 694K 
[ ]5PSQ-098.pdf2025-02-27 17:48 311K 
[ ]5PSQ-097.pdf2025-02-28 13:58 495K 
[ ]5PSQ-097-1.pdf2025-02-28 16:43 495K 
[ ]5PSQ-096.pdf2025-02-28 13:58 607K 
[ ]5PSQ-096-1.pdf2025-02-28 16:43 607K 
[ ]5PSQ-094.pdf2025-02-28 08:38 161K 
[ ]5PSQ-093-EFFECTIVENESS-AND-SAFETY-OF-DURVALUMAB-IN-UNRESECTABLE-OR-METASTATIC-CHOLANGIOCARCINOMA.pdf2025-02-27 17:48 164K 
[ ]5PSQ-092.pdf2025-02-27 17:48 656K 
[ ]5PSQ-091_Laakkonen-et-al-2025.pdf2025-02-27 17:48 489K 
[ ]5PSQ-090.pdf2025-02-17 14:01 272K 
[ ]5PSQ-088.pdf2025-02-17 14:01 494K 
[ ]5PSQ-087-Clinica-experience-with-bezlotoxumab-in-a-third-level-hospital.pdf2025-02-27 17:57 1.2M 
[ ]5PSQ-086-2.pdf2025-02-27 17:57 344K 
[ ]5PSQ-085-Safety-and-tolerance-profile-or-osimertinib-for-treatment-of-non-small-cell-lung-cancer.pdf2025-02-27 17:57 276K 
[ ]5PSQ-084.pdf2025-02-28 08:38 423K 
[ ]5PSQ-081.pdf2025-02-17 14:01 125K 
[ ]5PSQ-079.pdf2025-02-27 17:57 2.0M 
[ ]5PSQ-078.pdf2025-02-28 08:38 1.8M 
[ ]5PSQ-077-MARIA-PUENTE-IGLESIAS.pdf2025-02-27 17:57 718K 
[ ]5PSQ-076.pdf2025-02-27 17:57 6.1M 
[ ]5PSQ-074.pdf2025-02-17 14:01 1.1M 
[ ]5PSQ-072.pdf2025-02-17 14:01 1.0M 
[ ]5PSQ-071.pdf2025-02-17 14:01 475K 
[ ]5PSQ-070.pdf2025-02-17 13:36 425K 
[ ]5PSQ-069.pdf2025-02-17 14:06 7.4M 
[ ]5PSQ-068.pdf2025-02-28 08:38 2.5M 
[ ]5PSQ-067.pdf2025-02-17 14:06 712K 
[ ]5PSQ-066.pdf2025-02-27 17:57 698K 
[ ]5PSQ-065.pdf2025-02-28 08:38 348K 
[ ]5PSQ-063.pdf2025-02-17 14:06 90K 
[ ]5PSQ-062.pdf2025-02-27 17:57 191K 
[ ]5PSQ-060-LEVERAGING-THE-WHO-PHARMACOVIGILANCE-DATABASE-VIGIBASE-EXAMPLE-OF-THE-SAFETY-ANALYSIS-OF-177LuLu-DOTATATE.pdf2025-02-27 17:56 663K 
[ ]5PSQ-059-CASE-REPORT-UNEXPECTED-ADVERSE-REACTION-TO-68GaGa-DOTATOC.pdf2025-02-27 17:56 1.2M 
[ ]5PSQ-058.pdf2025-02-17 14:06 179K 
[ ]5PSQ-055.pdf2025-02-17 14:06 124K 
[ ]5PSQ-054.pdf2025-02-17 14:05 131K 
[ ]5PSQ-053.pdf2025-02-28 13:58 32K 
[ ]5PSQ-053-1.pdf2025-02-28 16:43 32K 
[ ]5PSQ-051.pdf2025-02-27 17:56 235K 
[ ]5PSQ-050.pdf2025-02-27 17:56 110K 
[ ]5PSQ-049.pdf2025-02-19 13:07 108K 
[ ]5PSQ-047.pdf2025-02-17 14:05 251K 
[ ]5PSQ-046.pdf2025-02-17 14:05 146K 
[ ]5PSQ-045.pdf2025-02-17 14:05 325K 
[ ]5PSQ-041.pdf2025-02-28 13:58 150K 
[ ]5PSQ-041-1.pdf2025-02-28 16:43 150K 
[ ]5PSQ-040.pdf2025-02-17 14:05 1.0M 
[ ]5PSQ-039.pdf2025-02-27 17:56 1.5M 
[ ]5PSQ-038.pdf2025-02-27 17:56 827K 
[ ]5PSQ-037.pdf2025-02-27 17:56 5.0M 
[ ]5PSQ-036.pdf2025-02-27 17:56 4.2M 
[ ]5PSQ-035.pdf2025-02-17 14:05 217K 
[ ]5PSQ-034.pdf2025-02-17 14:05 184K 
[ ]5PSQ-033.pdf2025-02-17 14:05 2.4M 
[ ]5PSQ-033-1.pdf2025-02-27 17:56 2.4M 
[ ]5PSQ-032.pdf2025-02-17 14:05 310K 
[ ]5PSQ-031.pdf2025-02-27 17:56 696K 
[ ]5PSQ-030.pdf2025-02-27 17:56 151K 
[ ]5PSQ-029.pdf2025-02-17 14:05 5.0M 
[ ]5PSQ-027-ORAL-TOLERANCE-INDUCTION-TO-COTRIMOXAZOLE-IN-IMMUNOSUPPRESSED-PATIENTS-WITH-A-HISTORY-OF-A-NON-SEVERE-HYPERSENSITIVITY-REACTION.pdf2025-02-28 13:58 2.1M 
[ ]5PSQ-027-ORAL-TOLERANCE-INDUCTION-TO-COTRIMOXAZOLE-IN-IMMUNOSUPPRESSED-PATIENTS-WITH-A-HISTORY-OF-A-NON-SEVERE-HYPERSENSITIVITY-REACTION-1.pdf2025-02-28 16:43 2.1M 
[ ]5PSQ-026.pdf2025-02-17 14:06 543K 
[ ]5PSQ-025.pdf2025-02-17 14:06 829K 
[ ]5PSQ-024.pdf2025-02-28 08:37 472K 
[ ]5PSQ-023.pdf2025-02-17 14:06 2.1M 
[ ]5PSQ-022.pdf2025-02-17 14:06 139K 
[ ]5PSQ-020.pdf2025-02-28 08:37 440K 
[ ]5PSQ-019.pdf2025-02-17 14:06 592K 
[ ]5PSQ-018.pdf2025-02-17 14:06 523K 
[ ]5PSQ-016-SIMULATION-OF-A-CYBERATTACK-IN-A-HOSPITAL-PHARMACY-DEVELOPMENT-OF-TOOLS-TO-ENSURE-CONTINUITY-OF-CARE.pdf2025-02-27 17:56 659K 
[ ]5PSQ-014.pdf2025-02-17 14:06 206K 
[ ]5PSQ-013.pdf2025-02-17 14:06 190K 
[ ]5PSQ-011.pdf2025-02-17 14:06 1.1M 
[ ]5PSQ-010.pdf2025-02-17 14:06 375K 
[ ]5PSQ-009-2.pdf2025-02-27 17:56 438K 
[ ]5PSQ-008.pdf2025-02-17 14:06 717K 
[ ]5PSQ-008-1.pdf2025-02-27 17:56 717K 
[ ]5PSQ-007.pdf2025-02-27 17:56 319K 
[ ]5PSQ-006.pdf2025-02-17 14:06 526K 
[ ]5PSQ-005.pdf2025-02-19 13:07 1.5M 
[ ]5PSQ-004.pdf2025-02-27 17:56 329K 
[ ]5PSQ-003.pdf2025-02-17 14:06 894K 
[ ]5PSQ-002.pdf2025-02-17 14:06 193K 
[ ]5PSQ-001.pdf2025-02-17 14:06 1.5M 
[ ]4CPS-242.pdf2025-02-27 17:56 17M 
[ ]4CPS-241.pdf2025-02-27 17:56 1.0M 
[ ]4CPS-240.pdf2025-02-18 13:12 26M 
[ ]4CPS-239.pdf2025-02-27 17:56 562K 
[ ]4CPS-238.pdf2025-02-28 08:37 166K 
[ ]4CPS-237.pdf2025-02-18 13:12 173K 
[ ]4CPS-236.pdf2025-02-19 13:07 249K 
[ ]4CPS-235.pdf2025-02-19 13:06 240K 
[ ]4CPS-232_UTK_EAHP_v3.pdf2025-02-18 13:12 498K 
[ ]4CPS-231.pdf2025-02-28 08:37 2.1M 
[ ]4CPS-230.pdf2025-02-27 17:56 386K 
[ ]4CPS-229-poster.pdf2025-02-27 17:56 353K 
[ ]4CPS-228-PDF.pdf2025-02-27 17:56 385K 
[ ]4CPS-224.pdf2025-02-18 13:12 466K 
[ ]4CPS-223.pdf2025-02-18 13:12 649K 
[ ]4CPS-221.pdf2025-02-18 13:12 211K 
[ ]4CPS-220.pdf2025-02-18 13:12 1.1M 
[ ]4CPS-219_REAL-WORLD-EFFECTIVENESS-OF-IBRUTINIB-MONOTHERAPY-IN-CHRONIC-LYMPHOCYTIC-LEUKEMIA.pdf2025-02-27 17:56 458K 
[ ]4CPS-217.pdf2025-02-18 13:12 233K 
[ ]4CPS-216.pdf2025-02-18 13:12 1.2M 
[ ]4CPS-213.pdf2025-02-18 13:12 402K 
[ ]4CPS-212.pdf2025-02-28 16:50 391K 
[ ]4CPS-209.pdf2025-02-27 17:56 872K 
[ ]4CPS-207.pdf2025-02-18 13:12 567K 
[ ]4CPS-205.pdf2025-02-28 08:37 443K 
[ ]4CPS-202-FORMULATION-OF-CLOBETASOL-AND-TACROLIMUS-URETHRAL-SYRINGES-AND-EFFICACY-IN-BALANITIS-XEROTICA-OBLITERANS-A-CASE-REPORT.pdf2025-02-18 13:12 253K 
[ ]4CPS-200.pdf2025-02-28 08:37 224K 
[ ]4CPS-199-poster.pdf2025-02-27 17:56 754K 
[ ]4CPS-198.pdf2025-02-28 16:50 295K 
[ ]4CPS-195-EAHP.pdf2025-02-18 13:12 194K 
[ ]4CPS-194.pdf2025-02-18 13:11 947K 
[ ]4CPS-193.pdf2025-02-18 13:11 243K 
[ ]4CPS-192.pdf2025-02-27 17:56 2.8M 
[ ]4CPS-191-EAHP_ber.pdf2025-02-19 13:06 862K 
[ ]4CPS-191-EAHP_ber-1.pdf2025-02-27 17:56 1.1M 
[ ]4CPS-190.pdf2025-02-27 17:56 324K 
[ ]4CPS-189.pdf2025-02-18 13:11 476K 
[ ]4CPS-188-C-CORBINAIS.pdf2025-02-27 17:55 1.3M 
[ ]4CPS-187.pdf2025-02-27 17:55 822K 
[ ]4CPS-185.pdf2025-02-18 13:11 264K 
[ ]4CPS-184.pdf2025-02-27 17:55 659K 
[ ]4CPS-183.pdf2025-02-18 13:11 182K 
[ ]4CPS-182.pdf2025-02-27 17:55 2.7M 
[ ]4CPS-181.pdf2025-02-28 13:58 890K 
[ ]4CPS-181-1.pdf2025-02-28 16:43 890K 
[ ]4CPS-180-ASSESSMENT-OF-CAPIVASERTIB-FOR-TREATMENT-OF-ADVANCED-BREAST-CANCER.pdf2025-02-18 13:11 526K 
[ ]4CPS-179.pdf2025-02-27 17:55 868K 
[ ]4CPS-178.pdf2025-02-18 13:11 1.0M 
[ ]4CPS-177.pdf2025-02-18 13:11 323K 
[ ]4CPS-176.pdf2025-02-27 17:55 406K 
[ ]4CPS-175.pdf2025-02-28 16:50 532K 
[ ]4CPS-174.pdf2025-02-27 17:55 341K 
[ ]4CPS-173.pdf2025-02-28 08:37 216K 
[ ]4CPS-172.pdf2025-02-19 18:31 399K 
[ ]4CPS-170.pdf2025-02-27 17:55 843K 
[ ]4CPS-167.pdf2025-02-18 13:11 369K 
[ ]4CPS-166_Poster_Mar-Panisello.pdf2025-02-18 13:11 662K 
[ ]4CPS-163.pdf2025-02-28 13:58 215K 
[ ]4CPS-163-1.pdf2025-02-28 16:43 215K 
[ ]4CPS-160.pdf2025-02-28 13:58 335K 
[ ]4CPS-160-1.pdf2025-02-28 16:43 335K 
[ ]4CPS-158.pdf2025-02-28 08:37 506K 
[ ]4CPS-157.pdf2025-02-27 17:55 679K 
[ ]4CPS-155.pdf2025-02-27 17:55 328K 
[ ]4CPS-154.pdf2025-02-28 16:50 645K 
[ ]4CPS-153.pdf2025-02-27 17:58 279K 
[ ]4CPS-152.pdf2025-02-18 13:11 213K 
[ ]4CPS-151.pdf2025-02-18 13:11 379K 
[ ]4CPS-150.pdf2025-02-18 13:11 1.4M 
[ ]4CPS-147.pdf2025-02-27 17:58 206K 
[ ]4CPS-145.pdf2025-02-27 17:58 771K 
[ ]4CPS-144.pdf2025-02-27 17:58 564K 
[ ]4CPS-142.pdf2025-02-27 17:58 544K 
[ ]4CPS-141​.pdf2025-02-27 17:58 515K 
[ ]4CPS-140-EAHP-POSTER-TSO.pdf2025-02-27 17:58 247K 
[ ]4CPS-139.pdf2025-02-27 17:58 794K 
[ ]4CPS-138.pdf2025-02-18 13:11 691K 
[ ]4CPS-137.pdf2025-02-27 17:58 352K 
[ ]4CPS-135.-PHARMACEUTICAL-INTERVENTIONS-ON-DIRECT-ORAL-ANTICOAGULANTS-IN-EMERGENCY-DEPARMENT.pdf2025-02-18 13:11 270K 
[ ]4CPS-134.pdf2025-02-27 17:58 644K 
[ ]4CPS-133.pdf2025-02-27 17:58 633K 
[ ]4CPS-130-R-START.pdf2025-02-27 17:58 921K 
[ ]4CPS-129.pdf2025-02-18 13:11 544K 
[ ]4CPS-128.pdf2025-02-19 18:31 1.0M 
[ ]4CPS-127.pdf2025-02-27 17:58 789K 
[ ]4CPS-124.pdf2025-02-27 17:58 164K 
[ ]4CPS-122.pdf2025-02-27 17:58 888K 
[ ]4CPS-121.pdf2025-02-18 13:11 674K 
[ ]4CPS-120_EAHP25.pdf2025-02-27 17:58 854K 
[ ]4CPS-118-ZCetkovic-et-al.pdf2025-02-27 17:58 484K 
[ ]4CPS-116.pdf2025-02-18 13:11 651K 
[ ]4CPS-114.pdf2025-02-18 13:11 1.3M 
[ ]4CPS-113.pdf2025-02-27 17:58 203K 
[ ]4CPS-112.pdf2025-02-18 13:11 300K 
[ ]4CPS-111.pdf2025-02-27 17:58 762K 
[ ]4CPS-110.pdf2025-02-18 13:11 514K 
[ ]4CPS-109.pdf2025-02-18 13:11 196K 
[ ]4CPS-108.pdf2025-02-18 13:11 207K 
[ ]4CPS-107.pdf2025-02-27 17:58 1.2M 
[ ]4CPS-105.pdf2025-02-18 13:11 1.0M 
[ ]4CPS-104.pdf2025-02-18 13:11 340K 
[ ]4CPS-103.pdf2025-02-27 17:58 236K 
[ ]4CPS-101.pdf2025-02-28 08:37 2.0M 
[ ]4CPS-100.pdf2025-02-28 08:37 341K 
[ ]4CPS-099.pdf2025-02-28 08:37 560K 
[ ]4CPS-098.pdf2025-02-18 13:11 1.2M 
[ ]4CPS-096.pdf2025-02-18 13:11 1.1M 
[ ]4CPS-095.pdf2025-02-18 13:11 354K 
[ ]4CPS-094.pdf2025-02-18 13:11 1.7M 
[ ]4CPS-093.pdf2025-02-18 13:11 569K 
[ ]4CPS-092-TREATMENTS-FOR-RET-ALTERED-ADVANCE-OR-METASTATIC-THYROID-CANCER-A-SYSTEMATIC-REVIEW.pdf2025-02-18 13:10 331K 
[ ]4CPS-091.pdf2025-02-18 13:10 171K 
[ ]4CPS-090.pdf2025-02-18 13:10 254K 
[ ]4CPS-089.pdf2025-02-18 13:10 543K 
[ ]4CPS-087.pdf2025-02-27 17:58 74K 
[ ]4CPS-086.pdf2025-02-18 13:10 931K 
[ ]4CPS-085.pdf2025-02-27 17:58 408K 
[ ]4CPS-084-EFFICACY-OF-OBETICHOLIC-ACID-IN-PATIENTS-WITH-PRIMARY-BILIARY-CHOLANGITIS-A-MULTICENTRE-STUDY-IN-REAL-LIFE.pdf2025-02-18 13:10 525K 
[ ]4CPS-083.pdf2025-02-18 13:10 191K 
[ ]4CPS-082.pdf2025-02-18 13:10 358K 
[ ]4CPS-081.pdf2025-02-18 13:10 366K 
[ ]4CPS-080.pdf2025-02-18 13:10 429K 
[ ]4CPS-075.pdf2025-02-18 13:10 190K 
[ ]4CPS-074.pdf2025-02-18 13:10 2.7M 
[ ]4CPS-073_Adina-Fesus_Poster.pdf2025-02-18 13:10 941K 
[ ]4CPS-072.pdf2025-02-18 13:10 236K 
[ ]4CPS-069.pdf2025-02-27 17:58 555K 
[ ]4CPS-067-Poster.pdf2025-02-27 17:58 592K 
[ ]4CPS-066.pdf2025-02-18 13:10 347K 
[ ]4CPS-064.pdf2025-02-18 13:10 734K 
[ ]4CPS-063.-Patient-satisfaction-long-acting-antiretroviral.pdf2025-02-22 12:30 356K 
[ ]4CPS-063.-Patient-satisfaction-long-acting-antiretroviral-1.pdf2025-02-27 17:58 356K 
[ ]4CPS-062.pdf2025-02-18 13:10 713K 
[ ]4CPS-061.pdf2025-02-27 17:58 636K 
[ ]4CPS-059_Predictive-Markers.pdf2025-02-22 12:29 786K 
[ ]4CPS-059_Predictive-Markers-1.pdf2025-02-27 17:58 786K 
[ ]4CPS-058-EAHP_fer.pdf2025-02-18 13:10 762K 
[ ]4CPS-057_Daniel-Fresan.pdf2025-02-18 13:10 521K 
[ ]4CPS-057.pdf2025-02-18 13:10 521K 
[ ]4CPS-056.-Efficacy-of-anti-calcitonin-gene-indirect-comparison.pdf2025-02-22 12:29 393K 
[ ]4CPS-056.-Efficacy-of-anti-calcitonin-gene-indirect-comparison-1.pdf2025-02-27 17:57 393K 
[ ]4CPS-055.pdf2025-02-18 13:10 2.1M 
[ ]4CPS-054.pdf2025-02-18 13:10 720K 
[ ]4CPS-053.pdf2025-02-18 13:10 467K 
[ ]4CPS-052.pdf2025-02-18 13:10 1.2M 
[ ]4CPS-051.pdf2025-02-18 13:10 1.4M 
[ ]4CPS-050.pdf2025-02-18 13:10 243K 
[ ]4CPS-049.pdf2025-02-18 13:10 926K 
[ ]4CPS-047.pdf2025-02-19 13:06 479K 
[ ]4CPS-046.pdf2025-02-18 13:10 944K 
[ ]4CPS-045.pdf2025-02-18 13:10 877K 
[ ]4CPS-044.pdf2025-02-18 13:10 941K 
[ ]4CPS-043.pdf2025-02-28 13:58 446K 
[ ]4CPS-043-1.pdf2025-02-28 16:43 446K 
[ ]4CPS-042.pdf2025-02-18 13:09 587K 
[ ]4CPS-041.pdf2025-02-18 13:09 1.1M 
[ ]4CPS-040.pdf2025-02-18 13:09 1.3M 
[ ]4CPS-039-SIX-MONTH-EVALUATION-OF-THE-CLINICAL-AND-ECONOMIC-IMPACT-OF-PHARMACEUTICAL-COUNSELING-IN-MULTIDISCIPLINARY-DAY-HOSPITALS-FOR-GERIATRICS.pdf2025-02-22 12:29 554K 
[ ]4CPS-039-SIX-MONTH-EVALUATION-OF-THE-CLINICAL-AND-ECONOMIC-IMPACT-OF-PHARMACEUTICAL-COUNSELING-IN-MULTIDISCIPLINARY-DAY-HOSPITALS-FOR-GERIATRICS-1.pdf2025-02-27 17:57 554K 
[ ]4CPS-038.pdf2025-02-27 17:57 555K 
[ ]4CPS-037.pdf2025-02-18 13:09 1.7M 
[ ]4CPS-036.pdf2025-02-22 12:29 400K 
[ ]4CPS-036-1.pdf2025-02-27 17:57 400K 
[ ]4CPS-035.pdf2025-02-18 13:09 255K 
[ ]4CPS-034.pdf2025-02-18 13:09 244K 
[ ]4CPS-033.pdf2025-02-18 13:09 1.1M 
[ ]4CPS-032-PALBOCICLIB-AND-RIBOCICLIB-DOSE-ADJUSTMENT-BY-TOXICITY-AND-ITS-IMPACT-IN-HEALTH-OUTCOMES.pptx.pdf2025-02-18 13:09 156K 
[ ]4CPS-031.pdf2025-02-18 13:09 646K 
[ ]4CPS-030.pdf2025-02-18 13:09 229K 
[ ]4CPS-029.pdf2025-02-18 13:09 522K 
[ ]4CPS-028.pdf2025-02-18 13:09 583K 
[ ]4CPS-028-poster.pdf2025-02-27 17:57 583K 
[ ]4CPS-027.pdf2025-02-18 13:09 261K 
[ ]4CPS-027-2.pdf2025-02-27 17:57 342K 
[ ]4CPS-027-1.pdf2025-02-22 12:29 342K 
[ ]4CPS-026.pdf2025-02-18 13:09 661K 
[ ]4CPS-025.pdf2025-02-18 13:09 210K 
[ ]4CPS-024.pdf2025-02-18 13:09 384K 
[ ]4CPS-022.pdf2025-02-19 18:31 657K 
[ ]4CPS-021.pdf2025-02-18 13:09 228K 
[ ]4CPS-019.pdf2025-02-18 13:09 3.0M 
[ ]4CPS-018.pdf2025-02-18 13:09 3.1M 
[ ]4CPS-017.pdf2025-02-18 13:09 571K 
[ ]4CPS-016-2.pdf2025-02-18 13:09 1.1M 
[ ]4CPS-015.pdf2025-02-18 13:09 1.1M 
[ ]4CPS-014-poster-SAFETY-PROFILE-OF-ENZALUTAMIDE-IN-PATIENTS-WITH-CASTRATION-RESISTANT-PROSTATE-CANCER-REAL-LIFE-DATA-1-1.pdf2025-02-27 17:57 956K 
[ ]4CPS-014-poster-SAFETY-PROFILE-OF-ENZALUTAMIDE-IN-PATIENTS-WITH-CASTRATION-RESISTANT-PROSTATE-CANCER-REAL-LIFE-DATA-.pdf2025-02-22 12:29 956K 
[ ]4CPS-013-poster-OPTIMIZATION-OF-EMPIRICAL-USE-OF-CEFTAZIDIMEAVIBACTAM-IN-A-MEDIUM-COMPLEX-IMPACT-OF-ANTIMICROBIAL-STEWARDSHIP-PROGRAM-MULTIDISCIPLINARY.pdf2025-02-22 12:30 1.0M 
[ ]4CPS-013-poster-OPTIMIZATION-OF-EMPIRICAL-USE-OF-CEFTAZIDIMEAVIBACTAM-IN-A-MEDIUM-COMPLEX-IMPACT-OF-ANTIMICROBIAL-STEWARDSHIP-PROGRAM-MULTIDISCIPLINARY-1.pdf2025-02-27 17:57 1.0M 
[ ]4CPS-012.pdf2025-02-18 13:09 374K 
[ ]4CPS-011.pdf2025-02-18 13:09 375K 
[ ]4CPS-010.pdf2025-02-18 13:12 648K 
[ ]4CPS-009.pdf2025-02-27 17:57 809K 
[ ]4CPS-008.pdf2025-02-18 13:12 544K 
[ ]4CPS-007.pdf2025-02-18 13:12 121K 
[ ]4CPS-005.pdf2025-02-18 13:12 167K 
[ ]4CPS-004.pdf2025-02-18 13:12 1.7M 
[ ]4CPS-002.pdf2025-02-18 13:12 1.0M 
[ ]4CPS-001.pdf2025-02-18 13:12 817K 
[ ]3PC-044.pdf2025-02-28 13:58 932K 
[ ]3PC-044-1.pdf2025-02-28 16:43 932K 
[ ]3PC-043.pdf2025-02-28 13:58 322K 
[ ]3PC-043-1.pdf2025-02-28 16:43 322K 
[ ]3PC-042.pdf2025-02-28 16:50 1.0M 
[ ]3PC-041_EAHP-poster_Epicutaneous-patch-test-preparation.pdf2025-02-27 17:57 204K 
[ ]3PC-040.pdf2025-02-28 08:37 486K 
[ ]3PC-039-Preparation-and-stability-of-RTA-Dexamethasone-dihydrogen-phosphate-hyaluronic-acid-intratympanal-solution_poster.pdf2025-02-28 16:50 1.6M 
[ ]3PC-038-.pdf2025-02-19 18:31 1.0M 
[ ]3PC-036_Poster-PDF.pdf2025-02-28 13:58 1.2M 
[ ]3PC-036_Poster-PDF-1.pdf2025-02-28 16:43 1.2M 
[ ]3PC-034.pdf2025-02-28 16:50 801K 
[ ]3PC-033.pdf2025-02-19 12:52 81K 
[ ]3PC-032.pdf2025-02-19 12:52 299K 
[ ]3PC-031.pdf2025-02-27 17:57 940K 
[ ]3PC-030.pdf2025-02-19 12:52 336K 
[ ]3PC-028.pdf2025-02-27 17:57 935K 
[ ]3PC-027.pdf2025-02-28 16:50 540K 
[ ]3PC-026.pdf2025-02-28 16:50 145K 
[ ]3PC-025.pdf2025-02-28 08:37 720K 
[ ]3PC-024.pdf2025-02-19 12:52 107K 
[ ]3PC-023-ZCetkovic-et-al.pdf2025-02-27 17:57 458K 
[ ]3PC-021.pdf2025-02-19 12:52 98K 
[ ]3PC-020-Paulsson.pdf2025-02-27 17:57 776K 
[ ]3PC-018.pdf2025-02-19 12:52 1.0M 
[ ]3PC-017.pdf2025-02-19 12:52 340K 
[ ]3PC-016.pdf2025-02-27 17:57 483K 
[ ]3PC-015.pdf2025-02-19 12:52 522K 
[ ]3PC-012.pdf2025-02-19 12:52 3.6M 
[ ]3PC-009.pdf2025-02-19 12:52 599K 
[ ]3PC-008.pdf2025-02-19 12:52 958K 
[ ]3PC-006.pdf2025-02-19 12:52 680K 
[ ]3PC-005.pdf2025-02-19 12:52 253K 
[ ]3PC-004.pdf2025-02-19 12:52 285K 
[ ]3PC-004-2.pdf2025-02-27 17:57 285K 
[ ]3PC-004-1.pdf2025-02-22 12:30 285K 
[ ]3PC-003.pdf2025-02-19 12:52 253K 
[ ]3PC-002.pdf2025-02-27 17:57 2.0M 
[ ]3PC-001.pdf2025-02-19 12:52 1.3M 
[ ]2SPD-018.pdf2025-02-19 13:00 282K 
[ ]2SPD-016.pdf2025-02-27 17:57 563K 
[ ]2SPD-015.pdf2025-02-28 08:37 551K 
[ ]2SPD-014.pdf2025-02-28 08:37 399K 
[ ]2SPD-013.pdf2025-02-28 13:58 725K 
[ ]2SPD-013-1.pdf2025-02-28 16:43 725K 
[ ]2SPD-012.pdf2025-02-28 08:37 723K 
[ ]2SPD-011.pdf2025-02-28 08:37 808K 
[ ]2SPD-010.pdf2025-02-28 13:58 453K 
[ ]2SPD-010-1.pdf2025-02-28 16:43 453K 
[ ]2SPD-009-PTS-poster.pdf2025-02-27 17:57 906K 
[ ]2SPD-008.pdf2025-02-28 08:37 704K 
[ ]2SPD-007.pdf2025-02-19 13:00 470K 
[ ]2SPD-006.pdf2025-02-19 13:00 487K 
[ ]2SPD-005.pdf2025-02-19 13:00 494K 
[ ]2SPD-004.pdf2025-02-19 13:00 791K 
[ ]2SPD-003.pdf2025-02-19 13:00 161K 
[ ]2SPD-002.pdf2025-02-28 13:58 707K 
[ ]2SPD-002-1.pdf2025-02-28 16:43 707K 
[ ]2SPD-001-2.pdf2025-02-27 17:57 1.0M 
[ ]1ISG-009.pdf2025-02-19 13:00 1.0M 
[ ]1ISG-006.pdf2025-02-19 13:00 655K 
[ ]1ISG-005-ANALYSIS-OF-PHARMACEUTICAL-INTERVENTIONS-IN-A-MULTIDISCIPLINARY-TELEPHARMACY-PROGRAMME.pdf2025-02-22 12:30 698K 
[ ]1ISG-005-ANALYSIS-OF-PHARMACEUTICAL-INTERVENTIONS-IN-A-MULTIDISCIPLINARY-TELEPHARMACY-PROGRAMME-1.pdf2025-02-27 17:57 698K 
[ ]1ISG-003.pdf2025-02-28 16:50 1.1M 
[ ]1ISG-001.pdf2025-02-19 13:00 763K 
Apache/2.4.56 (Debian) Server at eahp.eu Port 443